ArticleCancer2019

Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies.

Minny Bhatty et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.